Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

Novo Nordisk slashed its full-year sales and operating profit guidance. Wegovy and Ozempic sales are not what the company had ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

If you’ve spent any time in the real world lately, chances are you’ve heard of Ozempic, Wegovy, Mounjaro or semaglutide.

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...